Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)
Year: 2026
Type: article
Abstract: Gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) poses a substantial clinical burden in China. This updated guideline introduces a refined human epidermal growth factor receptor 2 (HER2) classification system (high, intermediate, low, absent) to redefine patient stratification for targeted therapy. It integrates cutting-edge evidence on standardized detection-including immunohistochemistry, in situ hybridization, and liquid biopsy-to overcome spatial-temporal heterogeneity. Recent progress in the use of HER2-targeted agents, including monoclonal antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, and bispecific antibodies, is systematically reviewed and presented to inform evidence-based clinical practice. These updates aim to optimize personalized HER2-targeted therapy and improve outcomes in GC/GEJC patients.
Source: Journal of Hematology & Oncology
Institutions: Peking University Cancer Hospital, Inner Mongolia Medical University, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Chinese Academy of Medical Sciences & Peking Union Medical College, Zhejiang Cancer Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Fudan University, Fudan University Shanghai Cancer Center, Anhui Medical University, First Affiliated Hospital of Anhui Medical University, First Hospital of China Medical University, China Medical University, Shanghai Medical College of Fudan University, Zhongshan Hospital, Hebei Medical University, Fourth Hospital of Hebei Medical University, Army Medical University, Southwest Hospital, Tongji University, Shanghai East Hospital, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,990
Awards: G6619374640, G8080246969
OpenAlex ID: W7160663168